Storage effect on viability and biofunctionality of human adipose tissue-derived stromal cells
Mizied Falah1, Anwar Rayan1, Samer Srouji2
1Drug Discovery Informatics Lab, QRC-Qasemi Research Center, Al-Qasemi Academic College, Baka El-Garbiah, Israel.
Cytotherapy
|August 16, 2015
Summary
Human adipose-derived stromal cells (ASCs) maintain viability and bone-forming capacity for up to 24 hours in a novel transplantation mixture. This formulation supports cell-based therapies for bone and joint disorders, enhancing accessibility.
Area of Science:
- Regenerative Medicine
- Cell Biology
- Biomaterials Science
Background:
- Human adipose-derived stromal cells (ASCs) show therapeutic potential for bone and joint disorders.
- Current clinical applications require optimized cell formulations for transplantation.
Purpose of the Study:
- To evaluate the impact of a specific transplantation mixture on ASC viability and biofunctionality.
- To assess ASC performance in bone formation following storage in the mixture.
Main Methods:
- ASCs were suspended in a mixture of PlasmaLyte A, hyaluronic acid, and OraGraft particles.
- Cell viability was assessed using trypan blue and AlamarBlue assays.
- In vitro adhesion and in vivo ectopic bone formation in mice were evaluated.
Main Results:
- Over 80% ASC viability was maintained for up to 24 hours in the transplantation mixture.
- Viability decreased to approximately 50% after 24 hours.
- Bone formation was comparable between ASCs stored for up to 24 hours and non-incubated controls.
Conclusions:
- The tested formulation supports ASC viability and functionality for at least 24 hours.
- This formulation can facilitate broader clinical application of ASC-based therapies.
- Enhanced accessibility of cell therapy for bone and joint disorders is anticipated.
Keywords:
OraGraftadipose tissue–derived cellscell functionalitycell viabilityhuman serum albuminhyaluronic acidtransplantation mixture
